Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Rockville, MD, US. The stock last traded at $28.00, down 3.61% on the session, giving a market capitalisation of $721.8M. On trailing twelve-month figures it carries a trailing P/E of -0.20, a net margin of 4030.7%. Its beta of -0.28 implies it has historically moved less than the broad market.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Faeth Therapeutics, Inc. is most often compared with the following Healthcare names: